Apptomics aims to establish its digital platform as the standard for monitoring movement disorders

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/monkeybusinessimages)
(Image: Getty/monkeybusinessimages)

Related tags BBK Digital biomarker Parkinson’s disease Clinical trials

Apptomics is working with BBK and Biotaware to develop the remote health-monitoring platform, which recently served as a digital biomarker to evaluate treatment effects as part of an essential tremor clinical trial.

Apptomics announced Monday that its digital platform E.V.A (Evaluation. Validation. Action) has been used successfully in a study for essential tremor. Researchers used the platform as an “exploratory digital biomarker”​ in addition to standard clinical scales to evaluate treatment effects.

Georgia Mitsi, PhD, MBA, Co-founder and CEO, Apptomics, told us app is being used in a sub study to look at the use of objective criteria and its role in evaluating movement disorders. 

Apptomics, which provides digital health solutions, partnered with the patient recruitment and engagement technology firm BBK Worldwide in 2016 to develop a suite of mobile apps for patients, caregivers, physicians, and payers. The company also is working with Biotaware to develop the platform, which it hopes will become the standard for monitoring movement disorders.

“BBK is an investor and has been commissioned to advance the user interface and assist in the evolution in the application,”​ Joan F. Bachenheimer, founding principal and CEO, BBK Worldwide, told us. BBK is working with Biotaware also to ensure the data integrity and the evaluation of the metrics, she said.

The E.V.A platform – originally dubbed iMotor – has been updated to include the addition of a digital spirography, a functional test of upper limb function. It also can be paired with electronic clinical outcome assessment (eCOA) and electronic data capture (EDC) platforms, according to the company.

Currently, E.V.A is being evaluated for its ability to help assess patient response to investigational treatments in a Phase III study in essential tremor as well as several Phase II studies in Parkinson’s disease and essential tremor.

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us


View more